Nexell Therapeutics Files Suit Against Miltenyi Biotec/AmCell
IRVINE, Calif.--(BW HealthWire)--March 2, 2000--Nexell Therapeutics Inc. (Nasdaq:NEXL), one of the world's leading suppliers of therapeutic products based on hematopoietic stem cell technology, announced today that it has filed suit in the U.S. District Court in Delaware against Miltenyi Biotec GmbH of Germany and its related U.S. companies, Miltenyi Biotec, Inc. and AmCell Corporation.
The suit charges Miltenyi with patent infringement, breach of contract and deceptive trade practices. Joining Nexell in the suit are Becton, Dickinson and Company and The Johns Hopkins University, both of whom have proprietary rights associated with Nexell's technology. Nexell intends to ask the court for damages and injunctive relief.
"We have an affirmative duty as a public company and a steward of important intellectual property rights to vigorously defend our hard-earned position," said L. William McIntosh, President and COO of Nexell. "We are open to reaching a business solution with Miltenyi and saving the cost and distraction of legal action."
Nexell Therapeutics Inc.
Located in Irvine, California, Nexell Therapeutics Inc. (Nasdaq:NEXL) is a cell therapy company whose mission is to put the healing power of the cell into the hands of physicians. Nexell is developing and marketing innovative ex vivo cell therapies and in vitro diagnostics for cancer, autoimmune, metabolic and genetic diseases. Nexell's lead product, the Isolex(R) 300i Magnetic Cell Selection System, is the only FDA approved device commercially available for the selection of hematopoietic stem cells and the removal of tumor cells from autologous peripheral blood as a component of aggressive cancer treatment. In addition, Nexell markets the Cytonex(TM) ICC Staining Kit and an extensive line of cell therapy preparation, storage and expansion products including the Cryocyte(TM), SteriCell(R) and Lifecell(R) brands.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward-looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. Among the factors which could affect the Company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are: the timely commencement and success of the Company's clinical trials and other research endeavors, delays in receiving FDA or other regulatory approvals, the development of competing therapies and/or technologies, the terms of any future strategic alliances, the possible need for additional capital, and any additional factors described from time to time in the Company's filings with the SEC.
NOTE TO INVESTORS AND EDITORS: Nexell Therapeutics Inc. press releases are available on the Internet through www.nexellinc.com and through Business Wire's web site at businesswire.com. The releases are also available at no charge through Business Wire's fax-on-demand service at 800/411-8792.
CONTACT:
Nexell Therapeutics Inc., Irvine
Tad Heitmann, 949/470-6516
KEYWORD: CALIFORNIA DELAWARE INTERNATIONAL EUROPE
BW1168 MAR 02,2000
5:30 PACIFIC
8:30 EASTERN
|
